US stock futures inch lower after Wall St marks fresh records on tech gains
Steven S. Williamson, President and CEO of Pulmonx Corp (NASDAQ:LUNG), recently sold shares worth $197,699. The stock sale, executed on March 3, 2025, involved 27,689 shares at a price of $7.14 each. The transaction comes as Pulmonx shares, currently trading at $8.19, have shown strong momentum with a 20.62% gain year-to-date, despite a recent 11% pullback last week. The transaction was part of covering tax obligations related to the vesting of Restricted Stock Units (RSUs) granted in March 2024.
Following the sale, Williamson’s direct ownership of Pulmonx shares stands at 194,342. Additionally, he acquired 181,696 RSUs, which vest quarterly over four years, and received 128,395 employee stock options, exercisable at $8.29, vesting monthly over four years.
In other recent news, Pulmonx Corp reported a strong fourth-quarter performance for 2024, with revenue reaching $23.8 million, a 23% increase from the previous year. This figure surpassed the consensus estimate of $22.3 million and highlighted the company’s robust international growth, with revenue outside the U.S. increasing by 42%. Despite a slight decrease in gross margins to 74%, Pulmonx’s earnings per share of -$0.33 exceeded forecasts, indicating improved financial management. Citi analysts responded to these developments by raising the company’s stock target to $8.00, maintaining a Neutral rating while acknowledging the potential for growth. Pulmonx’s management has provided guidance for 2025, projecting revenue between $96 million and $98 million, representing a growth of 16%-18% excluding foreign exchange impacts. The company continues to focus on expanding its market presence and product offerings, including the launch of new products and pilot initiatives. Pulmonx’s strategic initiatives aim to establish its Zephyr valve as a standard treatment for COPD, with ongoing efforts to increase physician adoption and expand geographically.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.